profit from every $100 of sales.
$0$100
Amneal Pharmaceuticals
$21.38-1.47% today
+85.6% in 1 year
1-year low $11.521-year high $21.71
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $103.38 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Amneal Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $2.21 billion in 2022 to $3.02 billion in 2025, with $72.1 million of profit last year.
SalesProfit
Amneal Pharmaceuticals vs. similar companies
Amneal Pharmaceuticals grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Amneal Pharmaceuticals | 103.4× · Very expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Amneal Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,993 | 2,094 | 2,212 | 2,394 | 2,794 | 3,019 | |
| 628 | 769 | 785 | 821 | 1,020 | 1,113 | |
| 91 | 153 | 189 | 239 | 348 | 398 | |
| 327 | 386 | 150 | 400 | 440 | 604 | |
| 68 | 13 | -130 | -84 | -117 | 72 | |
| 0.61 | 0.07 | -0.86 | -0.48 | -0.38 | 0.22 | |
| 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% | |
| 4.6% | 7.3% | 8.5% | 10.0% | 12.5% | 13.2% | |
| 3.4% | 0.6% | -5.9% | -3.5% | -4.2% | 2.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 4,006 | 3,940 | 3,799 | 3,473 | 3,501 | 3,678 |
| Cash | 341 | 248 | 26 | 92 | 111 | 282 |
| Total debt | 2,907 | 2,838 | 2,845 | 2,751 | 2,593 | 2,689 |
| Total liabilities | – | – | 3,615 | 3,453 | 3,611 | 3,750 |
| 303 | 360 | 298 | 20 | -109 | -71 | |
| 149 | 152 | 151 | 176 | 309 | 325 | |
| 2.2% | 3.8% | -2.3% | 4.9% | 6.5% | 11.5% | |
| 22.4% | 3.7% | -43.6% | -424.6% | 107.0% | -101.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 379 | 242 | 65 | 346 | 295 | 340 | |
| – | – | 91 | 69 | 75 | 114 | |
| – | – | -25 | 276 | 220 | 226 | |
| Dividends paid | 0 | – | – | – | – | – |
| – | – | – | – | – | – | |
| 21 | 28 | 32 | 27 | 28 | 32 |
Valuation
- 103.4×
- 21.5×
- –
- -105.8×
- 2.5×
- 33.0×
- 16.3×
- 3.0%
- 1.0%
- 0.0%
Profitability
- 36.9%
- 13.2%
- 2.4%
- 20.6%
- 11.8%
- 5.3%
- -144.7%
- 3.5%
- 12.8%
- 6.1%
Growth
- +8.7%
- −18.5%
- +22.6%
- –
- +29.1%
Financial health
- 4.0×
- -37.98
- 76.0%
- 1.6×
- 2.17
- 2.47
- 0.86
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 23%of 964
Top 44%of 898
Bottom 7%of 651
Bottom 43%of 911
Top 38%of 991
What analysts expect
- Average price target
- $17.00
- Range
- $15.00 – $19.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.27 | 0.17 | +58.8% |
| Feb 27, 2026 | 0.21 | 0.18 | +16.7% |
| Oct 30, 2025 | 0.17 | 0.13 | +30.8% |
| Aug 5, 2025 | 0.25 | 0.18 | +38.9% |
| May 2, 2025 | 0.21 | 0.15 | +40.0% |
| Feb 28, 2025 | 0.12 | 0.15 | −20.0% |
| Nov 8, 2024 | 0.16 | 0.13 | +23.1% |
| Aug 9, 2024 | 0.16 | 0.14 | +14.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
17No pass
Philip Fisher
12No pass
Peter Lynch
15No pass
Joel Greenblatt
14No pass
Charlie Munger
15No pass
Terry Smith
20No pass
Questions about Amneal Pharmaceuticals
Is Amneal Pharmaceuticals a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amneal Pharmaceuticals AI analysis
What does Amneal Pharmaceuticals do?
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Bridgewater, NJ, United States, with 8,700 employees.
Does Amneal Pharmaceuticals pay a dividend?
No. Amneal Pharmaceuticals does not pay a dividend at the moment.
Is Amneal Pharmaceuticals stock halal?
No. Amneal Pharmaceuticals does not pass our halal screen: its debt is 36% of its market value, at or above the 33% limit. How we check
How has Amneal Pharmaceuticals stock done over the past year?
Up 85.6% over the past twelve months, to $21.38. It traded between $11.52 and $21.71, close to its high.
Who are Amneal Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Amneal Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.